The Wegovy pre-filled pen: evidence, design, and what using one actually involves

What the clinical evidence says about the Wegovy pen and its results

The STEP 1 trial, published in the New England Journal of Medicine, randomised adults with obesity or overweight plus a weight-related condition and followed them for 68 weeks. Those receiving semaglutide 2.4mg lost an average of around 15% of their starting body weight alongside lifestyle changes, roughly three times the loss seen with placebo. That figure has anchored how clinicians and regulators talk about Wegovy's effectiveness ever since.

The picture has since grown. The MHRA approved a 7.2mg maintenance dose in January 2026, initially supplied as multiple pens per week, before approving a dedicated single-dose 7.2mg pen on 14 April 2026. Research at that higher dose reported approximately 20.7% average weight loss over 72 weeks. The approval was specifically for adults with a BMI of 30 or above, it does not apply to the cardiovascular or BMI-below-30 indications. If you want to understand how the dose ladder and pen formats compare across the Wegovy range, the Wegovy pen overview covers that in full.

One thing the trials make consistent: results depend heavily on concurrent lifestyle changes. The pen is a clinical tool, not a stand-alone solution. Every participant in STEP 1 also received dietary support and increased activity guidance, two things a prescriber will discuss with you as part of the consultation.

The pen's design and how a weekly injection actually works

The Wegovy pen is a pre-filled, single-patient-use auto-injector. Each pen contains four doses at the relevant strength, used once weekly. There is no vial, no syringe, and no manual needle attachment; the needle is built in and covered by the device mechanism until the moment of use. You press the pen against the skin, activate it, and the injection completes automatically, the device locks after use to confirm delivery and prevent re-use.

Injection sites are the abdomen (avoiding the area around the navel), the front or outer thigh, and the upper arm. Rotating between these sites at each injection reduces the chance of skin irritation or hardening at one spot. The guide to preparing your Wegovy pen walks through the full technique step by step, including how to check the pen before use and what a completed injection looks like.

Storage matters too. Wegovy pens must be kept refrigerated between 2°C and 8°C. Once in use, there is a room-temperature window, the exact duration is stated in the Patient Information Leaflet and you should follow that, not any figure you read online. Freezing ruins the medicine; a pen that has been frozen should not be used. If you are already considering a refillable injection pen for semaglutide, it is worth knowing that storage requirements remain equally important regardless of the device format you use. If you are travelling over a long weekend or a bank holiday (the kind of week where an order placed on a Thursday matters more than usual), plan storage in advance and keep a cool bag with an ice pack, not direct ice, to hand.

Side effects associated with the pre-filled pen and when to seek help

The most commonly reported side effects with semaglutide are gastrointestinal. Nausea is the most frequent, alongside vomiting, diarrhoea, constipation, and indigestion. These effects tend to be most noticeable in the first weeks after starting or following a dose increase, and for most people they ease as the body adjusts. The NHS semaglutide page lists the full side-effect profile with guidance on what is common, what is less common, and what warrants contacting a healthcare professional.

Pancreatitis is a less common but serious risk. The MHRA issued a Drug Safety Update in January 2026 specifically addressing this for GLP-1 medicines: if you experience severe, persistent abdominal pain that spreads to your back, with or without vomiting, you should seek urgent medical help and stop treatment until a clinician reviews it. That is not a situation to manage with a reduced dose or a wait-and-see approach.

Other signs that should prompt prompt medical attention include symptoms of a serious allergic reaction, significant dehydration from prolonged vomiting or diarrhoea, gallbladder symptoms such as sudden pain in the upper right abdomen, and any new or worsening low mood or thoughts of self-harm. You can report any suspected side effect directly to the MHRA at yellowcard.mhra.gov.uk.

Getting the Wegovy pen through a regulated UK pharmacy

Semaglutide for weight management is a prescription-only medicine. No legitimate route to the Wegovy pen bypasses a prescriber's assessment, and that assessment is where safe treatment begins, not where it gets in the way. A prescriber reviews your BMI, health history, current medicines, and any contraindications before a prescription is issued. Women of childbearing age will be asked about contraception, as the MHRA advises using reliable contraception during treatment and for a wash-out period before trying to conceive.

At nume, a GPhC-registered Independent Prescriber reviews every consultation personally. If you order before noon on a working day and your prescription is clinically approved, your pen is dispatched the same day and delivered by DPD the next working day, in plain packaging. Our pharmacy's GPhC registration is 9012878, you can verify it directly on the GPhC pharmacy register. More detail on what treatment costs and what that price covers is on the Wegovy prices page.

If you are already curious about how semaglutide's injection format compares to other pen formats, the semaglutide pre-filled pen page gives a broader view. And if injections are not for you, oral semaglutide (the Wegovy tablet) is now also available as an alternative treatment option worth exploring.